Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo Pharmaceuticals, a biopharmaceutical company, has presented a novel human hepatocyte growth factor knock-in model and announced data demonstrating strong preclinical activity of SCH 900105, a highly potent antagonist of hepatocyte growth factor/scatter factor.
Subscribe to our email newsletter
Additionally, data assessing fibroblast growth factor receptor-2 (FGFR-2) response to an FGFR antagonist in a novel FGFR-2 driven model were also presented.
According to Aveo, preclinical data demonstrated that SCH 900105 (AV-299) is efficacious in glioblastoma multiforme, non-small cell lung cancer, and pancreatic cancer models. In the U87 GBM model, SCH 900105 (AV-299) administration resulted in complete regressions even after withdrawal of treatment.
In addition, several combination studies performed with SCH 900105 (AV-299) and other targeted therapeutics, chemotherapies and anti-angiogenic agents demonstrated additive efficacy in vivo, the company said.
Tuan Ha-Ngoc, president and CEO of Aveo, said: “Preclinical data presented underscore the unique capability of our human response platform to guide drug development strategies for our lead antibody candidate SCH 900105 (AV-299), currently in Phase I clinical development, and reinforce the broad potential of our rapidly maturing antibody pipeline.”